Merck Biopharm osteoarthritis co-research agreement

Friday, 22 November, 2013

Biopharm has signed an agreement with Merck to cooperate with Merck Serono, the biopharmaceutical division of Merck, in their research activities directed towards the molecular engineering of a biologic compound for the treatment of osteoarthritis. Under the terms of the agreement, Biopharm and Merck Serono will enter a joint discovery project focusing on a potential pro-anabolic osteoarthritis modifying drug based on a growth factor derived from the Biopharm growth factor platform technology.

The aim of the research program, which is intended to run for two years, is to strengthen the potential beneficial effects of an existing wildtype protein, which is thought to drive hyaline joint cartilage formation during embryogenic development and seems to be associated with osteoarthritis.

Biopharm will provide variants of the wildtype protein and early preclinical research services focusing on the molecule properties to Merck Serono. In case of identification of any development candidates, Merck Serono will own exclusive development and commercialisation rights to the development candidates for osteoarthritis.

Related News

L'Oréal-UNESCO For Women In Science Fellows announced for ANZ

This year's program honours four women who are reshaping what leadership in research looks...

Peter Beattie appointed Chair of Brandon BioCatalyst

Brandon BioCatalyst has announced new board appointments to continue the scaling of Australian...

Virologist receives GSK Award for AI-based disease detection

Professor Edward Holmes has received the 2025 GSK Award for Research Excellence for his use of...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd